News | June 02, 2022
Vial to launch oncology CRO, Arati Rao named as First Advisor
The new Oncology CRO will aim to drive faster execution and higher quality trial outcomes for Oncology sponsors.
The new Oncology CRO will aim to drive faster execution and higher quality trial outcomes for Oncology sponsors.
Opdivo-based treatments are now approved for five indications in upper gastroesophageal cancers
Researchers found that the drug combination led to a sustained and tenfold increase in the production of CD8 T cells and natural killer cells
Glofitamab has the potential to offer a readily available, fixed-duration CD20xCD3 bispecific antibody treatment approach for people with aggressive lymphoma
Ulcerative colitis is a chronic, immune-mediated inflammatory bowel disease that can lead to substantial burden and often disability among patients
Results from the DELIVER and DAPA-HF Phase III trials demonstrate Dapagliflozin’ efficacy in heart failure regardless of ejection fraction
Includes thermostabilized Ebola vaccines
The partnership will further strengthen Olympus leadership in the diagnosis and staging of liver disease
PRP is a mixture of two proenzymes, trypsinogen and chymotrypsinogen from bovine pancreas administered by intravenous injection
Leading this effort was Cytel’s principal research scientist and Professor of Health Research Methods at McMaster University in Canada, Dr. Edward Mills
Subscribe To Our Newsletter & Stay Updated
